A conflict of interest (COI) exists when a researcher or speaker receives fees or funding from a pharmaceutical company in ways that could compromise the neutrality of the information they provide. When physicians receive that information without knowing about the COI, they treat it as impartial scientific evidence — but it may carry systematic bias. Japan's sales monitoring reports document specific cases: a promotional video citing a paper whose lead author was receiving remuneration as a medical expert adviser to the same company, and a web lecture where the COI slide appeared for only a fraction of a second — "long enough to blink through."
So What / So Why — The Core Problem
The reason COI non-disclosure matters is that physicians lose the ability to accurately gauge how much trust to place in information. The persuasive force of a paper or a lecture depends not only on the quality of the evidence but on who is presenting it. Even if the data are identical, when an author receives remuneration as a medical expert adviser to the drug's manufacturer, an independent review of study design, analysis, and conclusions becomes necessary. Without that background, a physician makes prescribing decisions missing one critical input.
The impact on patients is direct. Unnecessary drugs — or drugs whose risk-benefit balance has been distorted — get selected at higher rates. Delivering information without COI disclosure may not rise to the level of outright fabrication of evidence, but it structurally warps physician decision-making.
What makes the problem harder to solve is that the defence "we did disclose" can technically hold up. The COI slide was shown. But if it stayed on screen for only a blink, that is not meaningful disclosure. The fiscal year 2020 case — where the report explicitly states that the content could not be confirmed — illustrates exactly that loophole.
What / Where / Why / How — The Regulatory Breach
| Axis | Detail |
|---|---|
| What Specific violations | ① A paper cited in a video to support a product's safety was authored by a researcher receiving remuneration from the same company — with no disclosure in the video or slides. ② A COI slide was displayed at the opening of a web lecture, but for so short a time that attendees could not read it. ③ At a manufacturer-hosted web seminar, none of the presenters disclosed COI — because the company never asked them to. |
| Where Settings and media | Product promotional videos on healthcare professional information websites; presentation slides for in-hospital briefings; web lectures and web seminars. |
| Why Underlying drivers | The primary drivers are ③ omission (not saying something unless asked) and ④ externalisation of responsibility (not disclosing because the manufacturer never requested it). Because COI disclosure can dilute the positive image of a product, there is little incentive to disclose proactively. The system also rewarded the gap: whether a slide was included at all was checked; whether anyone could actually read it was not. |
| How Regulatory basis | The Ministry of Health, Labour and Welfare's "Guidelines on Sales Information Activities for Prescription Drugs" (2019) is structured around named principles, not numbered articles. The guideline's principle on the scope of information to be provided requires accurate disclosure of source information — including COI — for all cited literature. Its principle on conflict-of-interest management and transparency requires that COI information be presented in a form that attendees can actually review at company-hosted events. Suppression of information bearing on the credibility of scientific evidence is also inconsistent with the prohibition on exaggerated advertising under Article 66 of the Pharmaceuticals and Medical Devices Act and with the standards for appropriate advertising. The Japan Pharmaceutical Manufacturers Association's Guidelines for the Preparation of Product Information Compendiums likewise require explicit statement of COI for cited references. |
Case Records — In Full
Fiscal Year 2019 (Heisei 31)
Medium / Product area: Product promotional video on a healthcare professional information website / analgesic
What happened: A promotional video cited an original research paper as evidence of the product's safety. The paper's corresponding author was receiving remuneration as a "medical expert adviser" to the same company that manufactured and sold the product. No disclosure of this relationship appeared anywhere in the video.
Where it went wrong: The COI — that the cited paper's author was paid by the sponsoring company — was withheld from viewers, who were left unable to assess the possibility of bias in the evidence presented as safety support.
Direct quotation from the report: "Despite receiving remuneration as a 'medical expert adviser' to the manufacturer and seller of this product, no statement to that effect appeared in the video."
Medium / Product area: Presentation slides for in-hospital briefing / diuretic
What happened: Slides used at an in-hospital briefing cited a paper to support the product's efficacy. The paper carried a COI, but the slides contained no disclosure of it.
Where it went wrong: In a face-to-face setting where physicians receive information directly, the COI attached to the cited evidence was concealed while efficacy claims were made.
Direct quotation from the report: "Despite the existence of a COI, no statement to that effect appeared in the slides."
Fiscal Year 2020 (Reiwa 2)
Medium / Product area: Web lecture / sleep-onset medication
What happened: At the opening of a web lecture, a physician presenter who had a COI relationship with the organising company showed a COI slide. The slide was on screen for an extremely short time — too short for attendees to read its content.
Where it went wrong: The company maintained the appearance of disclosure while ensuring that attendees could not actually absorb the information. The act of disclosing was recorded; the purpose of disclosure — comprehension by attendees — was not achieved. A textbook case of formal compliance without substantive compliance.
Direct quotation from the report: "The COI slide was displayed for an extremely short time — barely long enough to blink through — and its content could not be confirmed."
Fiscal Year 2021 (Reiwa 3)
Medium / Product area: Web seminar / no specific product (multiple presenters)
What happened: At a manufacturer-hosted web seminar, none of the presenters disclosed COI. When asked, presenters explained that they had not disclosed because the manufacturer had never asked them to.
Where it went wrong: The organising company's failure to require COI disclosure from speakers meant that no COI information reached attendees throughout the entire seminar. The presenters' explanation — that they did not disclose because they were not asked to — in fact demonstrates that responsibility for disclosure management lies with the company.
Direct quotation from the report: "Because the manufacturer had not asked for COI disclosure, COI information was not displayed."
Fiscal Year 2022 (Reiwa 4)
Individual cases confirmed: 0. The web seminar case from fiscal year 2021 continued to be cited as a reference example of inappropriate sales information activity. The report's section on future challenges noted: "Physicians, pharmacists, and other presenters at seminars bear a personal obligation to disclose their own COI, but pharmaceutical companies are also expected to make presenters aware of the guideline requirements and to remind them not to present inappropriate content." Concern about recurrence remained explicit.
Fiscal Year 2023 (Reiwa 5)
Individual cases confirmed: 0. The summary section of the report repeated the same caution: "Physicians, pharmacists, and others presenting at seminars bear a personal obligation to disclose their own COI, but for seminars hosted by pharmaceutical companies, the company must also review slide content to check for activities that could constitute inappropriate sales information provision or for references with unclear sourcing, and must remind presenters to understand the guidelines and avoid inappropriate content." The same language recurred annually.
Fiscal Year 2024 (Reiwa 6)
Individual cases confirmed: 0. The report's summary continued virtually identical cautionary language about COI disclosure. The checklist item "✓ Failure to disclose the existence of a conflict of interest" remained on the published list.
Fiscal Year 2025 (Reiwa 7)
Individual cases confirmed: 0. The report recorded: "Physicians, pharmacists, and others presenting at seminars bear a personal obligation to disclose their own COI, but pharmaceutical companies hosting seminars must also review slide content to check for activities that could constitute inappropriate sales information provision or for references with unclear sourcing, and must ask presenters to understand the guidelines and avoid inappropriate content." The same concern has been repeated every year since the monitoring programme began — now seven consecutive years. The checklist item "✓ Failure to disclose the existence of a conflict of interest" remains published.
Learning from Past Incidents ── Map of 9 chapters
- Part 1: Data Misuse and Manipulation That Risk Factual Misrepresentation
- Part 2: Selective Data Extraction, Manipulation, and Presentation
- Part 3: Claims Without Evidence / Unreliable Data
- Part 4: Presenting Unapproved Indications and Dosage Regimens
- Part 5: Exaggerated Claims
- Part 6: Efficacy-Only Promotion / Safety Information Neglect
- Part 7: Disparagement of Competing Products
- Part 8 (this chapter): COI Non-Disclosure
- Part 9: Other Improper Sales Practices
- Formal disclosure is not the same as meaningful disclosure. Showing a COI slide for a fraction of a second does not count as disclosure. Disclosure only happens when attendees can actually read the content.
- The organising company bears management responsibility. 'I didn't disclose because I was never asked to' is not a defence. When a company fails to require COI disclosure from its presenters, the company has created the conditions for non-disclosure.
- Seven years of the same warning, never resolved. Individual cases have been zero since fiscal year 2021, yet every annual report has repeated the same COI disclosure caution. The absence of recorded cases does not mean the problem is solved — it may mean it has become harder to detect.
- Ministry of Health, Labour and Welfare, Pharmaceuticals and Medical Devices Act (Yakki-ho), Articles 66 and 68
- Ministry of Health, Labour and Welfare, "Guidelines on Sales Information Activities for Prescription Drugs" (25 September 2019)
- Ministry of Health, Labour and Welfare, "Prescription Drug Sales Information Activity Monitoring Programme" Annual Reports, Fiscal Years 2019–2025
- Japan Pharmaceutical Manufacturers Association, "Guidelines for the Preparation of Product Information Compendiums for Prescription Drugs"
- Ministry of Health, Labour and Welfare, "Prescription Drug Advertising Activity Monitoring Programme" Annual Reports (relating to appropriate advertising standards)